Newly named condition, “isolated diastolic hypotension,” can be difficult to treat while increasing risk of death.
New drug may slow the progression of chronic kidney disease in type 2 diabetics, increase kidney function and stave off dialysis.
With the acquisition, UAB takes a significant step toward making sophisticated cell therapy a part of patient care.
By mapping a patient’s genome, and their tumor’s, with whole-genome sequencing, physicians can use more targeted therapies.
Tigatuzumab, developed at UAB with Daiichi-Sankyo, targets aggressive, hard-to-treat tumors that make up 25 percent of all breast cancers